Jounce Therapeutics

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treats cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its product pipeline includes JTX-2011 (ICOS), JTX-4014 (PD-1), the Lead Macrophage Program, Macrophage Targeting, T Reg, B Cells, and Stromal Targeting. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Jounce Therapeutics is dedicated to transforming the treatment of cancer. The company is discovering and developing first-in-class cancer immunotherapies designed to harness the immune system to seek out and attack cancerous cells and tumors. Jounce’s proprietary product engine is driving this transformational approach, which has the potential to drive significantly more durable responses to treatment, extending and improving patients’ quality of life. Founded by world leaders in immunobiology, cancer biology and clinical and translational medicine, Jounce Therapeutics was launched in 2013 with funding from leading life sciences investor, Third Rock Ventures.

Investors need to pay close attention to Jounce Therapeutics (JNCE) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Jounce Therapeutics (JNCE) Stock?

Foundation Building Materials

Forterra

Hibbett Sports

Orion Energy Systems

A section of the U.S. business community - the small business segment - seems optimistic about the future despite trade-related hiccups.

Small Business Optimism Rises Amid Trade Jitters: 5 Top Picks

As of late, it has definitely been a great time to be an investor Jounce Therapeutics, Inc. (JNCE).

Jounce Therapeutics, Inc. (JNCE) Shares March Higher, Can It Continue?

Virtus LifeSci Biotech Clinical Trials ETF

Loncar Cancer Immunotherapy ETF

Global X Genomics & Biotechnology ETF

iShares U.S. Healthcare Providers ETF

Ironwood Pharma

Osmotica Pharmaceuticals Plc

ALPS Medical Breakthroughs ETF

Select Medical Holdings

Healthcare bounced back with an outperformance starting the fourth quarter.

Healthcare Sector Outperforming: 5 Best ETFs & Stocks QTD

Jounce Therapeutics, Inc. (JNCE) CEO Rich Murray on Q3 2019 Results - Earnings Call Transcript

Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of 28.89% and 19.48%, respectively, for the quarter ended September 2019.

Jounce Therapeutics, Inc. (JNCE) Q3 Earnings and Revenues Surpass Estimates

CAMBRIDGE, Mass., Oct.  01, 2019  (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that safety and efficacy data for JTX-4014 and a clinical trial in progress description of the vopratelimab Phase 2 EMERGE study will be presented in two poster sessions at the Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting, being held November 6-10, 2019 in National Harbor, Maryland.

Jounce Therapeutics to Present Two Posters from the JTX-4014 and Vopratelimab Programs at the Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting

CAMBRIDGE, Mass., Sept.  17, 2019  (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jacqui Fahey Sandell has been appointed as chief legal officer and corporate secretary.

Jounce Therapeutics Names Jacquelyn Fahey Sandell as Chief Legal Officer and Corporate Secretary

Jounce Therapeutics, Inc. (JNCE) CEO Richard Murray on Q2 2019 Results - Earnings Call Transcript

Jounce Therapeutics established updated deal with Celgene with the potential to earn up to $530 million in payments based on JTX-8064.

Jounce's Newly Restructured Deal Is Still Bullish For Its Long-Term Prospects

Celgene

Jounce Therapeutics Inc (NASDAQ: JNCE) shares are trading higher after the company announced an amended licensing agreement with Celgene Corporation (NASDAQ: CELG), the latter of which has agreed to be acquired by Bristol-Myers Squibb Co (NYSE: BMY).

What To Know About Jounce's Amended Licensing Deal With Celgene

Jounce Therapeutics Inc. (NASDAQ: JNCE) shares jumped on Wednesday after the company announced an update on its strategic collaboration with Celgene Corp.

Why Jounce Therapeutics Popped

Jounce Therapeutics, Inc. (JNCE) CEO Dr.

Jounce Therapeutics, Inc. (JNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Will Jounce Therapeutics, Inc. (JNCE) Report Negative Q1 Earnings?

The biopharma announced full-year 2018 operating results.

Here's Why Jounce Therapeutics Rose 39.3% in March

News for Jounce Therapeutics Stock (JNCE)